Hua Medicine (Shanghai) Ltd. updated on its clinical trails. The company has completed SEED (HMM0301), the first Phase III registration trial in China to investigate the efficacy and safety of dorzagliatin monotherapy in drug naïve Type 2 diabetes (T2D) patients, and announced the 52-week positive topline results with sustained efficacy, and good safety and tolerability profiles, it has completed DAWN (HMM0302), the second Phase III registration trial in China to investigate the efficacy and safety of dorzagliatin in T2D patients inadequately glycemic- controlled with metformin, and announced both the 24-week and 52-week positive topline results with sustained efficacy, and good safety and tolerability profiles. The company has presented data from SEED 24-week monotherapy clinical trial at the 80th American Diabetes Association (ADA) Annual Scientific Sessions, which demonstrated significant improvements in ß-cell function and 2h-PPG reduction. Presented additional data from DAWN at the Chinese Diabetes Society 's 2020 Scientific Meeting, demonstrating improvements in ß-cell function and reduction of insulin resistance. Also completed HMM0110, which demonstrated desirable pharmacokinetics profile in patients with end stage chronic kidney disease, indicating the potential use of dorzagliatin with no dose adjustment among T2D patients with moderate, severe and end stage chronic kidney disease (i.e. stages 3-5 of CKD). Completed HMM0111, investigating the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of dorzagliatin either alone or in combination with sitagliptin (a DPP-4 inhibitor), and demonstrated a clear synergistic effect in efficacy of blood glucose reduction and improvement of ß-cell function in T2D patients through regulation of GLP-1 secretion under combination therapy of dorzagliatin with sitagliptin Completed HMM0112, investigating the PK and PD characteristics of dorzagliatin and empagliflozin (a SGLT-2 inhibitor) as either monotherapy or combination therapy, and demonstrated a clear synergistic effect in efficacy of blood glucose reduction under combination therapy of dorzagliatin with empagliflozin with improvement of ß-cell function.